Alcobra dips on Fragile X data

Alcobra Ltd. (NASDAQ:ADHD) lost $1.09 (13%) to $7.30 on Wednesday after it said metadoxine ER missed the primary endpoint in a Phase II trial to treat Fragile X syndrome. The study showed no statistically significant difference between the treatment and placebo groups at reducing symptoms on the inattentive subscale of the ADHD Rating Scale (p=0.21); the difference favored placebo.

Alcobra said the candidate met two of five secondary endpoints in the 62-patient study's intent-to-treat population. Patients showed statistically significant improvements vs. placebo on the VABS Daily Living Skills domain (p=0.044) and KiTAP Distractability test (p=0.017). President and CEO Yaron Daniely said Alcobra would propose to FDA using VABS as a primary endpoint for future clinical trials; he did not provide a timeline. ...